Top Story

Age, diabetes duration increases risk for macrovascular complications

September 12, 2014

For patients with type 2 diabetes, macrovascular events and death are associated with age or age at diagnosis and diabetes duration, according to research published in Diabetologia.

Microvascular events, however, are only connected with diabetes duration and the effect is greater in younger patients, a study involving patients from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial showed.

figure In the Journals

Clopidogrel response impaired among patients with diabetes, CAD

September 4, 2014
Patients with diabetes and CAD experienced an impaired response to platelet P2Y12 receptor antagonist clopidogrel compared with those without diabetes in a recent…
In the Journals

Insulin use, dialysis predicted poor wound healing after endovascular therapy

August 28, 2014
Patients undergoing endovascular therapy for critical limb ischemia were significantly more likely to have non-healing wounds if they used insulin, were dependent on…
figure In the JournalsPerspective

DEFINITIVE LE published: Directional atherectomy effective regardless of diabetes status

August 27, 2014
Patients with or without diabetes who underwent directional atherectomy for peripheral artery disease experienced similar rates of primary patency at 12 months…
CME
figure

Lipid Forum II Highlights

This activity is supported by an educational grant from Genentech.

Risk stratification and appropriate therapies for various dyslipidemias remain difficult concepts for practitioners…
More »
CME
figure

Practical Lipidology: 2013

This activity is supported by an educational grant from Genentech.

The rise in the prevalence of obesity in the last few decades and its growing impact on health has driven the…
More »

Filter By:

In the Journals

Novel therapy lowered LDL in patients with diabetes, hypercholesterolemia

Cardiology Today, April 2014
ETC-1002, a novel agent in development by Esperion Therapeutics, lowered LDL levels by nearly 43% in patients with type 2 diabetes and…
FDA approvals Perspective

FDA approves Myalept for treatment of lipodystrophy

February 25, 2014
The FDA today approved metreleptin, in combination with diet, for the treatment of complications of leptin deficiency in patients with congenital…

FDA to review heart failure risk associated with saxagliptin

February 11, 2014
The FDA requested additional clinical trial data for saxagliptin due to potential heart failure risks, according to an announcement released…
FDA News

FDA to review heart failure risk associated with saxagliptin

Cardiology Today, April 2014
The FDA requested additional clinical trial data for saxagliptin due to potential heart failure risks, according to an announcement released…

CVS plans to stop all tobacco sales

February 6, 2014
CVS Caremark has announced that it will eliminate the sale of cigarettes and other tobacco products in all of its US pharmacies by October.There are…
figure CME

Risk Management in the Cardiovascular Disease Arena: Focus on Glycemic Control

February 1, 2014 Expires: 2/1/2015
Among the multiple comorbidities and complications that are associated with type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD) is the…
Meeting News Coverage

ACC announces late-breaking clinical trials

January 31, 2014
The American College of Cardiology has announced the line-up of late-breaking clinical trials scheduled for presentation at its Annual Scientific…
In the Journals

Insulin-treated diabetes linked with mortality in TAVR

January 20, 2014
The mortality rate among patients with insulin-treated diabetes was approximately 15% higher than the rate for those without diabetes at follow-up of…
In the Journals

Patients with hyperglycemia, gene mutation exhibit low prevalence of vascular complications

January 15, 2014
Patients with a mutation in the gene encoding the enzyme glucokinase demonstrated a low prevalence for microvascular and macrovascular complications…
FDA approvals

FDA approves dapagliflozin for type 2 diabetes

January 8, 2014
The FDA has approved dapagliflozin (Farxiga, Bristol-Meyers Squibb and AstraZeneca), according to a press release. The approval includes a…
More Headlines »